HER2-Low Breast Cancer: Pathological and Clinical Landscape
Paolo Tarantino(Harvard University), Giuseppe Curigliano(European Institute of Oncology), Fátima Cardoso(Breast Cancer Alliance), Dario Trapani(Harvard University), Stefania Morganti(Broad Institute), Emanuela Ferraro(University of Milan), Frédérique Penault‐Llorca(Inserm), Giulia Viale(Istituti di Ricovero e Cura a Carattere Scientifico), Sara M. Tolaney(Harvard University), Giuseppe Viale(University of Milan), Antonio Marra(Memorial Sloan Kettering Cancer Center), Fabrice André(Inserm), Javier Cortes(Instituto Oncológico Dr. Rosell), Erika Hamilton(Sarah Cannon)
Cited by 801
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2019|2.2k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k